CytoMed Therapeutics Ltd — Investor Relations & Filings

CytoMed Therapeutics is a clinical-stage company developing novel cell-based immunotherapies for a broad spectrum of cancers. The company focuses on creating "off-the-shelf" allogeneic therapies using its proprietary technologies to expand and engineer rare immune cells, primarily gamma delta (γδ) T cells and Natural Killer (NK) cells. These therapeutic cells are derived from healthy donors and can also be generated from induced pluripotent stem cells (iPSCs). Its pipeline encompasses multiple strategies, including unmodified cell treatments and advanced Chimeric Antigen Receptor (CAR)-modified cells, such as its CAR-γδ T cell technology. The company's mission is to produce effective and more affordable cellular treatments for both solid and hematological cancers.